Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 7,062 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Urological Disease Clear all
Completed Phase 4 Interventional

Osteopenia and Renal Osteodystrophy: Evaluation and Management

NCT00108394
View directory record Official record
Conditions
Osteopenia, Renal Osteodystrophy
Interventions
pamidronate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Fructose on Blood Fats in Dialysis Patients and Healthy Volunteers

NCT00234156
View directory record Official record
Conditions
End-stage Renal Disease
Interventions
oral fructose and high fat diet
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Not applicable Interventional

Study of Home-Embedded Palliative Care for Hemodialysis-Dependent End-Stage Renal Disease

NCT05471622
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
Nudge for PHPC Referral
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer

NCT00436657
View directory record Official record
Conditions
Peritoneal Neoplasms, Retroperitoneal Neoplasms, Gastrointestinal Neoplasms, Adenocarcinoma, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Adrenocortical Carcinoma, Wilms Tumor, Rhabdomyosarcoma, Desmoplastic Small Round Cell Tumor
Interventions
CHPP of Cisplatin, Abdominal Surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 2, 2012 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery

NCT01688973
View directory record Official record
Conditions
Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma
Interventions
Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Tivantinib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
214
States / cities
Tucson, Arizona • Anaheim, California • Baldwin Park, California + 154 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Uric Acid Lowering Trial in Youth Onset T2D

NCT03899883
View directory record Official record
Conditions
Diabetic Kidney Disease, Hyperuricemia, Diabetes, Diabetes Mellitus, Type 2, Type2 Diabetes, Type 2 Diabetes Mellitus, Diabetic Nephropathies, Diabetes Complications
Interventions
Pegloticase 8 MG/ML [Krystexxa]
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 21, 2026, 6:33 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain

NCT01060254
View directory record Official record
Conditions
Cystitis, Interstitial, Urologic Diseases, Urinary Bladder Diseases, Cystitis
Interventions
Placebo, JNJ-42160443
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Glendora, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

NCT01200394
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
PF-00489791, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
63
States / cities
Huntsville, Alabama • Glendale, Arizona • Tempe, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 21, 2026, 6:33 AM EDT
Terminated Not applicable Interventional Results available

Carvedilol and Micro T-Wave Alternans in Hypertensives With Chronic Kidney Disease

NCT00638222
View directory record Official record
Conditions
Vascular Disease, Kidney Disease
Interventions
Carvedilol and Placebo
Other
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Toledo, Ohio • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 13, 2014 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Pharmacokinetic and Safety Trial of Emraclidine in Participants With Renal Impairment Compared With Participants With Normal Renal Function

NCT05940402
View directory record Official record
Conditions
Renal Impairment
Interventions
Emraclidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
5
States / cities
Tustin, California • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 21, 2026, 6:33 AM EDT
Not listed Not applicable Interventional

Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients With Renal Cell Carcinoma

NCT04424472
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Ultrasonography
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 21, 2026, 6:33 AM EDT
Recruiting No phase listed Observational

Ethicon Pelvic Mesh Post Market Clinical Follow-up Registry

NCT04829175
View directory record Official record
Conditions
Stress Urinary Incontinence, Pelvic Organ Prolapse
Interventions
Intervention
Device
Lead sponsor
Ethicon, Inc.
Industry
Eligibility
21 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2038
U.S. locations
4
States / cities
New Haven, Connecticut • Durham, North Carolina • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Repeat Oral Doses of Darapladib (SB-480848) in Subjects With Severe Renal Impairment

NCT01711723
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib 160 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 21, 2026, 6:33 AM EDT
Recruiting Not applicable Interventional

Technology Assisted Collaborative Care Intervention to Improve Patient-centered Outcomes in Dialysis Patients

NCT06978127
View directory record Official record
Conditions
Chronic Kidney Disease Requiring Hemodialysis
Interventions
Technology Assisted Stepped Collaborative Care, Usual Care Arm
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Albuquerque, New Mexico • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Transfusion Trigger After Operations in High Cardiac Risk Patients

NCT03229941
View directory record Official record
Conditions
Myocardial Infarction, Coronary Revascularization, Acute Renal Failure
Interventions
Blood Transfusion
Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
1,424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
16
States / cities
Little Rock, Arkansas • Loma Linda, California • Long Beach, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 21, 2026, 6:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Percutaneous Nephrolithotomy Versus Extracorporeal Shock Wave Lithotripsy

NCT00873054
View directory record Official record
Conditions
Kidney Stones
Interventions
Not listed
Lead sponsor
CAMC Health System
Other
Eligibility
18 Years to 90 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
Charleston, West Virginia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

NCT00141037
View directory record Official record
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions
Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2016 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Phase 3 Interventional

TroVax Renal Immunotherapy Survival Trial

NCT00397345
View directory record Official record
Conditions
Clear Cell Renal Carcinoma
Interventions
Trovax, Placebo, Standard of care therapy
Biological
Lead sponsor
Oxford BioMedica
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
46
States / cities
Tucson, Arizona • Little Rock, Arkansas • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Oct 21, 2026, 6:33 AM EDT
Recruiting Not applicable Interventional

Impact of Unrestrictive Exercise Following Mid-Urethral Sling Surgery

NCT02316275
View directory record Official record
Conditions
Stress Urinary Incontinence
Interventions
No post-operative activity restrictions, Standard post-operative activity restriction
Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2031
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 21, 2026, 6:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

BVA-200 vs BVA-100 Validation Study

NCT06227819
View directory record Official record
Conditions
Heart Failure, High Blood Pressure, High Cholesterol, Anemia, Diabetes, Thyroid Diseases, Kidney Diseases, Clotting Disorder, Trauma, Other Disease
Interventions
BVA-200
Diagnostic Test
Lead sponsor
Daxor Corporation
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Oak Ridge, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2024 · Synced Oct 21, 2026, 6:33 AM EDT
Completed No phase listed Observational Results available

Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

NCT00744939
View directory record Official record
Conditions
Fibrosis, Kidney Failure, Renal Insufficiency
Interventions
Gadopentetate dimeglumine (Magnevist, BAY86-4882)
Drug
Lead sponsor
Bayer
Industry
Eligibility
2 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
26
States / cities
Phoenix, Arizona • Chula Vista, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Phase 3 Interventional Results available

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

NCT03386539
View directory record Official record
Conditions
Pediatric Heart Transplantation, Immunosuppression, Chronic Kidney Diseases, Cardiac Allograft Vasculopathy, Heart Transplant Failure and Rejection, Post-transplant Lymphoproliferative Disorder, Heart Transplant Infection
Interventions
Everolimus, Tacrolimus, Mycophenolate Mofetil
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 21 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 21, 2026, 6:33 AM EDT
Not listed No phase listed Observational

Onco4D(TM) Biodynamic Chemotherapy Selection for Bladder Cancer Patients

NCT03739177
View directory record Official record
Conditions
Bladder Cancer
Interventions
Onco4D Biodynamic Chemotherapy Selection Assay
Diagnostic Test
Lead sponsor
Animated Dynamics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 21, 2026, 6:33 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

NCT03963895
View directory record Official record
Conditions
End Stage Renal Disease, Thrombosis
Interventions
AB002 Dose 1, AB002 Dose 2, placebo
Drug
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 21, 2026, 6:33 AM EDT